Akari Therapeutics, Plc - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
AKTX Nasdaq 2830 www.akaritx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Akari Therapeutics, Plc

Akari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference - Aug 27th, 2026 7:01 am
Akari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy - Aug 18th, 2026 6:53 am
Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform - Aug 13th, 2026 2:15 pm
Akari Therapeutics Releases CEO Corner Highlighting Strategic WhiteHawk Collaboration and the Expanding Opportunity for Dual-Payload ADC Innovation - Aug 4th, 2026 6:50 am
Akari Therapeutics CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology Opportunity - Jul 22nd, 2026 6:40 am
Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics - Jul 21st, 2026 5:05 am
Akari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory Board - Jul 7th, 2026 6:55 am
Akari Therapeutics Completes Previously Announced PIPE, Strengthening Balance Sheet Ahead of Potential Key Clinical and Regulatory Milestones - Jun 29th, 2026 6:45 am
European Equities Traded in the US as American Depositary Receipts Surge in Monday Trading - Jun 15th, 2026 9:09 am
European Equities Traded in the US as American Depositary Receipts Track Higher in Tuesday Trading - Jun 9th, 2026 9:11 am
Akari Therapeutics Releases CEO Corner Reflecting on Evolving ADC Landscape and Akari’s Differentiated PH1 Payload Platform Following ASCO 2026 - Jun 4th, 2026 7:30 am
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading - Jun 2nd, 2026 9:08 am
Akari Therapeutics Highlights 1st ASCO Abstract Acceptance - May 28th, 2026 4:33 pm
Akari Therapeutics Discusses Breakthrough Potential of AKTX-101 and Novel Spliceosome-Modulating ADC Platform in Virtual Investor “What This Means” Segment Following ASCO Abstract Acceptance - May 28th, 2026 7:17 am
Akari Therapeutics Reports Breakthrough Preclinical Data Demonstrating Synergistic Activity of AKTX-101 with KRAS Inhibition in KRAS-Mutated Pancreatic Cancer Models - May 21st, 2026 3:01 pm
Akari Therapeutics Announces $5.5 Million Private Placement Offering - May 21st, 2026 6:30 am
Akari Therapeutics to Present at A.G.P.’s Annual Healthcare Company Showcase - May 18th, 2026 7:05 am
Akari Therapeutics Secures Key European Patent For Its Novel RNA Splicing Modulator ADC Payload, Strengthening Global IP Estate For All Major Global Markets - May 12th, 2026 6:33 am
Akari Therapeutics Secures Australian Patent Approval, Further Expanding Global Protection of Its Proprietary PH1 RNA Splicing Modulator ADC Payload - Apr 27th, 2026 6:35 am
European Equities Traded in the US as American Depositary Receipts Edge Higher in Wednesday Trading - Apr 22nd, 2026 9:13 am